The user has accepted their hair loss and uses finasteride and minoxidil, with past use of RU58841 and dutasteride. They seek advice on supplements to slow down graying hair.
The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.
Fluridil was discussed as a hair loss treatment, with some users experiencing side effects like lethargy and chest tightness. Users also mentioned other treatments like RU58841 and finasteride, with mixed opinions on their effectiveness.
The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.
Some users believe creatine may accelerate hair loss, while others see no effect. Opinions are mixed, with some suggesting using treatments like finasteride to counter potential effects.
A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
A 34-year-old male documents his hair growth journey using the iRestore Elite laser cap, biotin, and Pure Synergy Organic Superfood Capsules, after unsuccessful hair transplant and previous treatments with minoxidil and finasteride. Replies suggest using finasteride or dutasteride instead and caution against excessive use of the laser cap.
miR-205, a tiny RNA, can stimulate hair growth by softening aging hair follicle stem cells in mice. Future tests aim to see if this can work in humans.
A 29-year-old is using liposomal topical finasteride/minoxidil and low-level light therapy (LLLT) to improve hair growth, showing significant progress in crown recovery. The user prefers liposomal topicals to avoid side effects from oral finasteride and uses the iRestore Essential device for LLLT.
A user shared their positive experience with finasteride, noting significant hair regrowth over two years without using other treatments. They reported initial brain fog but no other side effects, and others in the conversation expressed encouragement and shared their own experiences with finasteride.
The user stopped finasteride for family planning but plans to restart it and is considering dutasteride. Users discuss the safety of finasteride during family planning, with some sharing experiences of having healthy children while on the medication.
A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.
Hair regrowth treatments are effective in mice but not yet available for humans. The discussion humorously highlights frustration over this disparity and mentions a project to genetically modify elephants to resemble mammoths.
Finasteride treatment is being considered, and it's advised to track DHT, testosterone, estradiol, and SHBG levels to monitor hormonal changes. These tests will help understand the treatment's impact.
The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
A 23-year-old male noticed hair loss and started using finasteride 1mg, initially experiencing significant shedding which reduced after 100 days. He switched from the brand Andropel to Folcres due to availability in Argentina.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.
GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.
The user expresses positivity about managing hair loss and celebrates good hair days. They mention using finasteride (Propecia) as part of their treatment.